Cell Potency Assay Using pS6 Phosphorylation for Batch Consistency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing potency assays for therapeutic cellular compositions, such as graft facilitating cells (FCs) and alpha beta TCR+ T cells, struggle to reliably measure batch-to-batch consistency due to complex biological pathways and varying therapeutic mechanisms, making it difficult to identify relevant product attributes.
Innovation Solution
A method involving contacting FCs and/or alpha beta TCR+ T cells with mitogenic stimuli to determine the number of cells where ribosomal S6 protein is phosphorylated (pS6), using fluorescently-labeled antibodies and FACS analysis to quantify potency, which can be performed before or after freezing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If complex biological pathways are used to determine potency, then therapeutic mechanism accuracy is improved, but assay complexity and difficulty of measurement increase
Solution Approach 1:
The patent extracts the essential therapeutic mechanism signal by focusing solely on pS6 phosphorylation status, separating this key indicator from the complexity of entire biological pathways. This allows potency assessment without requiring measurement of multiple pathway components simultaneously.
Solution Approach 2:
pS6 phosphorylation serves as an intermediary marker that indirectly reflects the functional state of complex biological pathways. Instead of directly measuring complex pathway activities, the assay uses pS6 as a simplified mediator that captures the essential therapeutic response signal.
2Measurement precision
If multiple biological markers are measured to account for varying therapeutic mechanisms, then measurement comprehensiveness is improved, but assay time and productivity decrease
Solution Approach 1:
The patent extracts only the critical measurement needed for potency assessment - pS6 phosphorylation status - eliminating the need to measure multiple other biological markers. This single-marker approach maintains comprehensive potency assessment while dramatically improving assay throughput.
3Reliability
If batch-to-batch consistency is ensured through rigorous testing, then product reliability is improved, but manufacturing time and productivity decrease
Solution Approach 1:
The patent replaces complex multi-parameter biological testing with a streamlined flow cytometry-based measurement of pS6 phosphorylation. This substitution maintains reliable batch consistency testing while significantly reducing the time required per batch assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a rapid and quantitative assessment of FCs and alpha beta TCR+ T cells' potency, ensuring at least 30% of these cells are pS6+, enabling reliable determination of therapeutic doses and batch consistency.
Implementation Method 1
the number of FCs and/or alpha beta TCR+ T cells in the sample in which pS6 is phosphorylated is determined using a fluorescently-labeled antibody against pS6
Data Source
AI summary
This disclosure provides a potency assay for evaluating the potency of facilitating cells and/or alpha beta TCR+ T cells.